T memory stem cells (T~SCM~), a rare subset of memory lymphocytes endowed with enhanced capacity of self-renewal and the potential to reconstitute the full repertoire of memory and effector cells, have recently emerged as a central player in several physiological and pathological processes. T~SCM~ cells have been shown to mediate superior anti-tumor responses ([@bb0020], [@bb0015]), harbor leukemic cancer stem cells ([@bb0045]), and serve as a reservoir for HIV infection ([@bb0010]). Because of these wide-ranging clinical implications, it is of critical importance to improve our understanding of the molecular events that induce or maintain T~SCM~ cells.

In this issue of *EBiomedicine*, Scholz et al. used pharmacological and genetic approaches to identify mTOR as a key signaling pathway regulating the formation of CD4^+^ and CD8^+^ T~SCM~ cells ([@bb0050]). It has previously been demonstrated in murine ([@bb0020]) and human ([@bb0015]) models that the formation of T~SCM~ cells can be promoted by triggering WNT/β-catenin signaling. The finding that inhibition of the mTOR pathway can also favor the generation of T~SCM~ cells has significant therapeutic implications as rapamycin and other mTOR inhibitors are FDA-approved agents that have already been used in T cell adoptive therapy clinical trials (clinicaltrials.gov.; [NCT00074490](ctgov:NCT00074490){#ir0005}, [NCT01239368](ctgov:NCT01239368){#ir0010}). As such, the contribution of Scholz et al. may accelerate the field in terms of bringing T~SCM~ cells into the clinical arena.

T~SCM~ cells are an ideal cell population to employ in T cell-based immunotherapies because of their enhanced capacity to engraft and ability to persist for the long-term. Using a human-into-mouse xenogeneic transplantation model, the authors found that T~SCM~ cells manufactured in rapamycin had increased persistence relative to control naïve or central-memory T cells, recapitulating prior observations obtained using naturally occurring T~SCM~ cell populations ([@bb0015]). These findings are also consistent with a body of literature indicating that rapamycin-resistant human Th1/Tc1 cells have a remarkable ability to repopulate xenogeneic hosts and mediate graft-versus-host disease effects ([@bb0005]). Additional in vivo functional endpoints, however, will be needed to determine the therapeutic potential of the rapamycin-generated T~SCM~ cell populations as manufactured by Scholz et al.

There is a growing interest around the possibility of targeting metabolism for immunotherapeutic interventions as it has become clear that metabolism can profoundly influence T cell functionality and fate commitment. Up to this point, the metabolic profile of T~SCM~ cells has remained elusive. Now, Scholz et al. shed new light on the metabolic regulation of human CD4^+^ T~SCM~ cells and have revealed that, similar to naïve and memory T cell populations, T~SCM~ cells rely on fatty acid oxidation as a primary source for ATP synthesis. These findings are fundamental because they open up the possibility to promote the formation and maintenance of T~SCM~ cells through the manipulation of fatty acid metabolism.

While underlying a central role for mTOR in the generation of T~SCM~ cells, Scholz et al. dispute a role for WNT/β-catenin signaling. The authors argue that the WNT activator, TWS119, promoted T~SCM~ cell generation not by the conventionally recognized mechanism (GSK3β inhibition and subsequent β-catenin stabilization) but rather via an off-target effect that involved mTOR inhibition; their conclusion was based in part on their observations that neither a physiological WNT3A ligand nor alternative GSK3β inhibitors supported T~SCM~ formation in their hands. However, the authors used WNT3A at concentrations 100-fold lower than those used in previous studies that found an active role of WNT3A in the generation of both murine and human T~SCM~ cells ([@bb0020], [@bb0040]). In their experiments, the lack of activity of the GSK3β antagonist indirubin-3-monoxime was potentially attributable to its weak selectivity and inability to trigger downstream WNT signals ([@bb0035]). In sharp contrast, the highly selective, 6-bromoinduribin derivatives, which are capable of stabilizing β-catenin ([@bb0035]), have successfully been employed to generate T~SCM~ cells ([@bb0020]). It is also important to underscore that the authors did not provide evidence of the ability of these 'ineffective' agents to activate WNT/β-catenin signaling. Indeed, Scholz et al. employed as a WNT operational readout the phosphorylation of GSK3β serine 9, a post-translational modification mediated by AKT and not involved in WNT signaling ([@bb0030]) (gold standard assays would consist of measurement of unphosphorylated β-catenin and WNT-reporter activity). In a final attempt to support their conclusion of TWS119 action outside of the GSK3β/WNT pathway realm, the authors used an elegant model involving β- and γ-catenin deficient T cells. However, conclusions based on these experiments carry the major caveat that WNT signal transmission is substantially maintained in double-deficient T cells ([@bb0025]). Further research will therefore be required to more definitively test the extent to which GSK3β inhibitors such as TWS119 might mediate their effect on T~SCM~ cells independent of the WNT pathway.

In summary, Scholz et al. have tackled a critical issue in biomedicine relating to human CD4^+^ and CD8^+^ T memory stem cell generation and function. Although the molecular mechanism(s) of T~SCM~ cell generation remain nebulous vis-à-vis the relative role of WNT/β-catenin or mTOR modulation, the current report certainly provides a nidus of information that will guide subsequent investigations. Hopefully, with the attainment of a refined molecular understanding and the development of alternative pharmacologic inhibitors, an ability to effectively modulate T~SCM~ cells for therapeutic purposes will be realized.
